Received Apr 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | LN0589 | IM / LA |
| FLU3 | INFLUENZA (SEASONAL) (FLUARIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | N737Y | IM / OT |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 1 | PE9G5 | IM / RA |
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 4ZC23 | IM / LA |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 4799G | IM / OT |
I noticed when doing a routine chart audit for vaccines that the Priorix MMR vaccine was given intramuscularly, when it should only be given subcutaneously. When I asked the nurse who administered the vaccines about this, she did not report any adverse events or outcomes at the time of vaccination. I called GSK and they had internal studies suggesting it is still more than 96% effective when given IM and immunize.org suggests that the dose does not need to be repeated. We did attempt to contact the patient to follow-up and have not yet gotten a hold of them. I also noticed when auditing the chart that the nurse gave two vaccines (influenza and Tdap) in the gluteus muscle. This is not a preferred site, but per immunize.org should still count as valid. I reviewed vaccination technique with this nurse, including how to give up to three IM injections in each deltoid. I also reviewed that Priorix should only be give subcutaneously.